PGPIPN
A milk-derived hexapeptide from bovine beta-casein with immunomodulatory, anticancer, and hepatoprotective properties studied primarily in ovarian cancer and liver disease models.
What is PGPIPN?
PGPIPN (Pro-Gly-Pro-Ile-Pro-Asn) is a six-amino-acid peptide corresponding to residues 63-68 of bovine beta-casein. It is naturally encrypted within milk protein and released during enzymatic digestion. Its three proline residues make it unusually resistant to further degradation by digestive enzymes, allowing it to survive the gastrointestinal tract and reach systemic circulation when taken orally. Originally identified for its immunomodulatory properties — enhancing macrophage phagocytosis and lymphocyte proliferation — it has since been studied for anticancer effects (particularly against ovarian cancer) and for protecting the liver from alcohol-induced damage.
What PGPIPN Is Investigated For
PGPIPN is a milk-derived hexapeptide from bovine beta-casein studied for ovarian cancer growth suppression (via BCL2-mediated apoptosis), overcoming cisplatin resistance, immune enhancement, and hepatoprotection against alcohol-induced liver damage. The strongest preclinical signal is in ovarian cancer xenograft models, where high-dose PGPIPN reduced tumor volume by ~68% — exceeding the 42% reduction seen with 5-fluorouracil in the same study — with selective cytotoxicity toward cancer over normal cells in vitro. Cisplatin-sensitization via HSF1/HSP70 downregulation and liver-protection via the PERK/eIF-2α ER stress pathway are additional mechanistically characterized findings. No human clinical trials have been conducted in any indication, and the critical caveat on the entire evidence base is that nearly all of the preclinical work originates from a single research program at Anhui Medical University in China with no independent multi-laboratory replication. The proline-rich structure plausibly supports oral bioavailability, but human pharmacokinetic data is absent. This is a candidate molecule, not a therapeutic — substituting it for evidence-based oncology or hepatology care is not appropriate.
History & Discovery
PGPIPN was identified as a bioactive fragment of bovine beta-casein corresponding to residues 63–68 of the parent protein, released during enzymatic digestion of milk by gastrointestinal proteases. The hexapeptide belongs to the broader category of food-derived bioactive peptides — sequences encrypted within dietary proteins that become biologically active only after proteolytic release in the gut. Initial characterization in the immunology literature focused on its capacity to enhance macrophage phagocytosis and lymphocyte proliferation; the unusual proline density (three of six residues) made it a natural candidate for studies of digestion-resistant peptides with potential systemic exposure after oral intake. Most of the subsequent work — anticancer activity in ovarian cancer cell lines and xenografts, attenuation of cisplatin resistance through HSF1/HSP70 modulation, and protection against alcoholic liver injury — has come from a research program at Anhui Medical University in China across roughly the 2010s and early 2020s. The footprint is mechanistically interesting and reasonably broad in terms of pathway coverage, but it remains heavily concentrated within one institutional research program, has not generated human clinical trial data in any indication, and has not produced the kind of independent multi-laboratory replication that would lift PGPIPN out of the early preclinical category.
How It Works
PGPIPN is a tiny, digestion-resistant peptide from milk protein that works through multiple pathways. In cancer cells, it triggers programmed cell death by suppressing the survival protein BCL2 and can help overcome chemotherapy resistance. In the immune system, it boosts the activity of macrophages (immune cells that engulf pathogens) and promotes lymphocyte proliferation. In the liver, it reduces inflammation, oxidative stress, and the ER stress response that drives alcohol-related damage.
PGPIPN exerts anticancer effects primarily through apoptosis induction: it downregulates BCL2 (anti-apoptotic) while upregulating Bax (pro-apoptotic), shifting the BCL2/Bax ratio toward programmed cell death in ovarian cancer cells (SKOV3, COC1, and primary tumor cells). It inhibits invasion and metastasis by repressing MTA1 (metastasis-associated protein 1) and upregulating NM23H1 (metastasis suppressor). In cisplatin-resistant cells, PGPIPN reduces HSF1/HSP70 signaling, downregulates MDR1 (P-glycoprotein) and ERCC1 (DNA repair protein), and induces G2/M cell cycle arrest, synergistically enhancing cisplatin sensitivity. Hepatoprotective effects involve attenuation of ER stress through the PERK/eIF-2alpha pathway, reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), decreased oxidative stress markers (MDA), increased antioxidant enzyme activity (SOD, GSH-PX), and regulation of lipid metabolism via ACC phosphorylation and PPAR-gamma upregulation. Immunomodulatory activity includes enhanced macrophage phagocytosis of sheep red blood cells and stimulation of splenic lymphocyte proliferation in rodent models.
Evidence Snapshot
Human Clinical Evidence
None. No human clinical trials have been published for PGPIPN in any indication.
Animal / Preclinical
Moderate. Multiple animal studies show dose-dependent tumor suppression in ovarian cancer xenograft mice (up to 68% volume reduction) and hepatoprotection in alcoholic liver disease models. Immune enhancement demonstrated in rat and mouse models. However, most studies originate from a single research group.
Mechanistic Rationale
Moderate. Multiple molecular pathways have been identified (BCL2/Bax, HSF1/HSP70, MTA1/NM23H1, PERK/eIF-2alpha), but the primary direct molecular target remains unclear. Mechanisms are plausible but not yet independently replicated.
Research Gaps & Open Questions
What the current literature has not yet settled about PGPIPN:
- 01Independent replication outside the originating Anhui Medical University research program — nearly all efficacy and mechanistic claims trace to a single institutional research orbit.
- 02Human pharmacokinetics — absorption (particularly the proline-resistance hypothesis for oral bioavailability), distribution to ovarian or hepatic tissue, metabolism, and clearance have not been characterized in humans.
- 03Phase I human safety — no first-in-human dosing studies have been conducted in any indication.
- 04Direct molecular target — although multiple downstream pathways are implicated (BCL2/Bax, HSF1/HSP70, MTA1/NM23H1, PERK/eIF-2alpha), the primary receptor or upstream binding partner that initiates these effects remains unidentified.
- 05Selectivity for cancer cells over normal cells — preliminary cell-culture data suggests selective cytotoxicity, but the threshold for normal-tissue toxicity in vivo across organ systems has not been mapped.
- 06Comparative efficacy versus established cisplatin-resensitization strategies — PGPIPN's preclinical synergy with cisplatin has not been benchmarked against other investigational chemosensitizers.
Forms & Administration
PGPIPN has only been used in research settings. In animal studies, it was administered via oral gavage at doses ranging from 0.025-4 mg/kg body weight (liver studies) or at concentrations of 0.15-15 micromolar in cell culture. In xenograft tumor studies, concentrations up to 0.50 g/L were used. The peptide's proline-rich structure confers oral bioavailability due to resistance to digestive enzymes. No human dosing has been established. PGPIPN is not commercially available as a therapeutic agent. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no human dosing convention for PGPIPN because no human studies have been conducted. In the published preclinical work, oral gavage in mice has used 0.025–4 mg/kg body weight in liver-protection studies; cell culture studies have used 0.15–15 micromolar concentrations; and ovarian cancer xenograft studies have used concentrations up to roughly 0.50 g/L in the dosing solution. Any human-equivalent dose is pure extrapolation and not supported by clinical data.
Frequency
In animal studies, dosing has been daily during the experimental window (typically 1–8 weeks depending on model). No human frequency is established.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
No human cycle convention exists. Animal experiments have used continuous daily dosing across the experimental window rather than cyclic protocols.
Protocol Notes
Critical context: PGPIPN is a research compound, not a therapeutic product. It is not commercially available as a peptide therapeutic, is not sold by mainstream peptide vendors as a finished product, and has no clinician-facing protocol. The proline-rich structure does plausibly support oral bioavailability — the three proline residues out of six make the backbone unusually resistant to gastrointestinal peptidase cleavage — but actual human pharmacokinetic data is absent. Anyone considering use of PGPIPN outside of a research setting should understand that they are extrapolating from cell-culture and rodent studies in a small body of work originating from one research group, with no human safety, dosing, or efficacy data to anchor to. This is fundamentally a candidate compound rather than a usable therapeutic.
PGPIPN is not FDA-approved for any indication. The preclinical anticancer and hepatoprotective findings are mechanistically interesting but do not justify use in any human clinical context, particularly not as a substitute for evidence-based oncology care or hepatology management.
Timeline of Effects
Onset
No characterized onset profile in humans. In rodent ovarian cancer xenograft studies, tumor growth suppression became apparent over weeks of continuous dosing. In acute alcoholic liver injury models, hepatoprotective effects were observed within the experimental window of single-dose or short-course pretreatment.
Peak Effect
In xenograft studies, maximal tumor volume reduction (around 68% at the highest dose) was observed at the end of the multi-week dosing window. In liver injury models, peak hepatoprotective biomarker effects were measured at end-of-experiment timepoints. No human peak-effect data exists.
After Discontinuation
Not characterized. The peptide's plasma half-life in any species has not been published in detail. Effects on tumor or liver biomarkers in animal models likely fade after dosing stops, but this has not been systematically tracked in published work.
Common Questions
Who PGPIPN Is NOT For
- •Active malignancy under treatment — despite preclinical anticancer signal, layering an unstudied investigational peptide onto active oncology care has no safety basis and could complicate response assessment or interact unpredictably with chemotherapy regimens.
- •Active liver disease requiring clinical management — PGPIPN's preclinical hepatoprotective data should not be substituted for hepatology evaluation.
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data.
- •Known milk-protein allergy — although PGPIPN is a defined synthetic sequence and not a milk-protein extract, hypersensitivity in patients with severe casein allergy has not been studied and warrants caution.
Drug & Supplement Interactions
There are no documented clinical drug interactions for PGPIPN because no human pharmacovigilance studies exist. What follows is theoretical and derived from the preclinical mechanistic work. The most consequential theoretical interaction is with cisplatin and other platinum-based chemotherapy. The published rationale for PGPIPN in ovarian cancer is precisely a cisplatin-sensitization effect via HSF1/HSP70 pathway downregulation; this is positioned as a synergistic interaction in the Anhui Medical University research, but synergy in cell culture does not establish clinically safe co-administration, and the in vivo pharmacology of combined exposure has not been characterized in humans. Concurrent use during any chemotherapy regimen should not be undertaken outside a formal clinical trial. Theoretical interactions also exist with other HSP70-modulating investigational agents and with immunomodulatory therapy given the macrophage and lymphocyte effects observed in immunology models. CYP-mediated interactions are not described and at the small doses involved are unlikely. Patients on any regular medication should disclose investigational peptide use to their prescribing clinician, though again, PGPIPN is not realistically encountered as a finished therapeutic product.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved for any indication
- • No human clinical trials have been conducted
- • All data comes from cell culture and animal models
- • Optimal human dosing is completely unknown
What We Don't Know
Human safety, pharmacokinetics, and efficacy are entirely unestablished. All research to date has been preclinical (in vitro and animal studies), primarily from a single research group at Anhui Medical University in China. No human clinical trials have been published.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a drug, dietary supplement ingredient, or food additive. PGPIPN is exclusively a research compound and is not commercially available as a finished therapeutic product.
International
Not approved as a medicine in any regulatory jurisdiction. Not on the EMA, MHRA, TGA, or Health Canada lists of approved peptide therapeutics. Some research-chemical suppliers sell synthetic PGPIPN for laboratory use, not for human consumption.
Sports & Competition
Not specifically named on the WADA Prohibited List. Because it is not approved by any governmental health authority for human therapeutic use, injectable PGPIPN would fall under WADA's S0 catch-all category for unapproved substances. The point is largely academic given that PGPIPN is not commonly used in athletic or supplement contexts.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
PGPIPN is a proven natural anticancer agent because it comes from milk.
Reality
It is a candidate molecule based on cell-culture and rodent xenograft data from one research program. Calling it a 'proven' anticancer agent — or a natural one in any therapeutically meaningful sense — overstates the evidence by orders of magnitude. Milk origin tells you about its biochemical lineage, not about its safety or efficacy in humans.
Myth
Drinking milk delivers therapeutic doses of PGPIPN.
Reality
PGPIPN is encrypted within beta-casein and released only when the parent protein is digested by specific proteolytic conditions. Whether dietary milk consumption yields any meaningful systemic exposure to the intact hexapeptide in humans has not been quantified, and the doses used in animal studies are not realistically achievable through dietary intake.
Myth
PGPIPN can replace cisplatin in ovarian cancer treatment.
Reality
The published rationale is that PGPIPN may resensitize cisplatin-resistant cells, not replace cisplatin. Even that resensitization claim is from cell-culture and animal work; no human clinical trial has tested PGPIPN in any oncology indication. Substituting it for evidence-based oncology care would be dangerous.
Myth
PGPIPN is safe because preclinical studies showed minimal normal-cell toxicity.
Reality
Preliminary normal-cell-line data is encouraging but does not establish in vivo safety across organ systems, in long-term dosing, or in human physiology. No formal toxicology study to regulatory standards has been performed.
Published Research
7 studiesBioactive hexapeptide reduced the resistance of ovarian cancer cells to DDP by affecting HSF1/HSP70 signaling pathway
Milk-derived hexapeptide PGPIPN prevents and attenuates acute alcoholic liver injury in mice by reducing endoplasmic reticulum stress
Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress
PGPIPN prevented and treated alcohol-induced fatty liver in mice via ACC/PPAR-gamma modulation and oxidative stress reduction.
Construction of an anticancer fusion peptide (ACFP) derived from milk proteins and an assay of anti-ovarian cancer cells in vitro
The milk-derived fusion peptide ACFP suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways
The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes
PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2
Demonstrated PGPIPN inhibits SKOV3 proliferation and induces apoptosis via BCL2 downregulation; 68% tumor reduction in xenograft mice.
Quick Facts
- Class
- Milk-Derived Bioactive Hexapeptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 7PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.